1. Indications and Usage
\nInvestigational Use:
\nLerociclib is an investigational drug being studied for the treatment of adults with solid tumors, including triple-negative breast cancer (TNBC) and other CDK4\/6 pathway-driven malignancies.
\nCurrent Status:
\nNot currently approved for commercial use in the United States or the European Union.
\n2. Dosage and Administration
\nRecommended Dosage (Clinical Trial Context):
\nStandard Dose: The recommended dose in clinical trials has been 200 mg to 400 mgadministered orally once daily or twice daily, in combination with other agents (e.g., paclitaxel or endocrine therapy).
\nNote: Dosing schedules are subject to change based on Phase 2\/3 trial protocols.
\nAdministration Instructions:
\nAdminister orally with or without food.
\nSwallow tablets whole; do not crush or chew.
\n3. Mechanism of Action
\nCDK4\/6 Inhibitor:
\nLerociclib is a potent, highly selective, and orally bioavailable inhibitor of cyclin-dependent kinases 4 and 6 (CDK4\/6).
\nPhysiological Effect:
\nIt binds to the ATP-binding pocket of CDK4 and CDK6, inhibiting their activity. This prevents the phosphorylation of the retinoblastoma protein (pRb), leading to cell cycle arrest at the G1 phase and inhibition of tumor cell proliferation.
\n4. Safety and Warnings
\nNeutropenia:
\nDecreases in neutrophil counts have been observed. Monitor complete blood counts (CBC) prior to starting treatment and periodically during treatment. Dose reductions or interruptions may be required.
\nFatigue and Asthenia:
\nPatients may experience significant fatigue.
\nEmbryo-Fetal Toxicity:
\nBased on its mechanism of action, lerociclib can cause fetal harm when administered to a pregnant woman.
\n5. Adverse Reactions
\nMost Common (Based on Clinical Trials):
\nNeutropenia, leukopenia, fatigue, nausea, vomiting, diarrhea, decreased appetite, and hair color changes.
\n6. Drug Interactions
\nCYP3A Substrates:
\nLerociclib is metabolized primarily by CYP3A4. Co-administration with strong CYP3A inhibitors (e.g., ketoconazole) or inducers (e.g., rifampin) may significantly alter lerociclib exposure.
\n7. Pharmaceutical Information
\nChemical Description:
\nLerociclib Hydrochloride is a small molecule selective CDK4\/6 inhibitor.
\nStorage:
\nStore at controlled room temperature. Keep in the original package to protect from moisture.<\/p>\n","protected":false},"excerpt":{"rendered":"
Brand Name: \u6c5d\u4f73\u5b81\u00ae(Rujianing\u00ae)
\nGeneric Name: Lerociclib Hydrochloride
\nStrength: 50 mg per tablet, 42 tablets per bottle
\nManufacturer: Quotient Sciences – Philadelphia, LLC
\nMarketing Authorization Holder: Genor Biopharma (USA), Inc.\uff08\u5609\u548c\u751f\u7269\u7f8e\u56fd\u516c\u53f8\uff09\uff0c\u5883\u5185\u6301\u8bc1 \/ \u63a8\u5e7f\u4f01\u4e1a\uff1a\u4ebf\u817e\u533b\u836f\uff08\u82cf\u5dde\uff09\u6709\u9650\u516c\u53f8
\nApproval Date in China: May 29, 2025
\nRegistration Number: \u56fd\u836f\u51c6\u5b57 HJ20250063
\nStorage: Store at room temperature (15\u201330\u2103), protected from light and moisture; keep out of reach of children<\/p>\n
Price&Cost:Contact Us now for the best price of Lerociclib Hydrochloride(Rujianing)<\/p>\n","protected":false},"featured_media":3176,"comment_status":"open","ping_status":"closed","template":"","meta":[],"product_brand":[],"product_cat":[27],"product_tag":[],"class_list":["post-3174","product","type-product","status-publish","has-post-thumbnail","product_cat-tablets","first","instock","shipping-taxable","product-type-simple"],"yoast_head":"\n